Indication
In adults aged 18 years and older with T2DM as an adjunct to diet and exercise to improve glycaemic control: • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • In addition to other medicinal products for the treatment of diabetes.

Medicine details

Medicine name:
ertugliflozin (Steglatro)
SMC ID:
SMC2102
Pharmaceutical company
MSD
BNF chapter
Endocrine system
Submission type
Full submission
Status
Advice due date:
14 January 2019
SMC meeting date:
04 December 2018
Patient group submission deadline:
05 November 2018